New Insights into the Role of Metformin Effects on Serum Omentin-1 Levels in Acute Myocardial Infarction: Cross-Sectional Study
Table 2
Biochemical changes and serum omentin-1 level in acute MI in the patients treated with metformin prior to acute MI in comparison with normal healthy control subjects.
Biochemical parameters
Group III () Mean ± SD
Group I () Mean ± SD
95% CI Upper–lower limits
S. omentin-1 pg/mL
27.13 ± 1.55
25.43 ± 1.2
27.7088–26.5512
<0.0001
S. troponin-I pg/mL
21.202 ± 3.483
75.453 ± 5.62
21.4395–20.9645
<0.0001
FBG mg/dL
118.96 ± 9.704
137.75 ± 13.139
122.5835–15.3365
<0.0001
Total cholesterol mg/dL
140.96 ± 30.091
152.33 ± 16.877
152.1962–129.7238
0.0475
TG mg/dL
138.66 ± 10.366
149.34 ± 23.31
142.5307–134.7893
<0.0001
HDL mg/dL
51.23 ± 5.882
54.43 ± 8.355
53.4264–49.0336
0.0058
VLDL mg/dL
27.64 ± 2.082
29.86 ± 4.662
27.7088–26.5512
<0.0001
LDL mg/dL
62.08 ± 3.834
68.13 ± 3.937
62.2667–61.8933
<0.0001
AI
0.072 ± 0.008
0.078 ± 0.009
0.075–0.069
0.0003
SPB mmHg
123.16 ± 9.042
140.33 ± 8.773
126.5363–119.7837
<0.0001
DPB mmHg
75.50 ± 1.643
82.16 ± 8.773
76.1135–74.8865
<0.0001
Group I: patients received metformin prior to acute MI. Group III: normal healthy controls. ;. FBG: fasting blood glucose, TG: triglyceride, HDL: high density lipoprotein, VLDL: very low density lipoprotein, LDL: low density lipoprotein, AI: atherogenic index, SPB: systolic blood pressure, and DPB: diastolic blood pressure.
